close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Latest News about Doug Drysdale

Recent news which mentions Doug Drysdale

Psychedelics Policy Is Shifting In Washington: Here's What One Biotech CEO Sees Coming
Tickers CYBN
Tags FDA Exclusives Doug Drysdale
From Benzinga
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression
Tickers CYBN
Tags Cannabis major depressive disorder Doug Drysdale
From Benzinga
Cybin Reports Access To $101M To Sustain Deuterated Psychedelics Programs, Q2 Numbers & 2024 Goals
Tickers CYBN
Tags Psychedelics Markets Cannabis
From Benzinga
Cybin Stock Down On Laying Off 15% Of Workforce As Part Of A Streamlining Clinical Alignment
Tickers CYBN
Tags premium News Doug Drysdale
From Benzinga
Cybin Approved For First In-Human Dosing Of DMT Molecule CYB004, Milestone For Anxiety Disorder Treatment
Tickers CYBN DMT
Tags first/in/human dosing CYB004 Markets
From Benzinga
Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family
Tickers CYBN MSSTF
Tags MSSTF Cybin Doug Drysdale
From Benzinga
Cybin Announces First Dosing In Human Trial With Proprietary Psychedelic Drug For Depression
Tickers CYBN
Tags Biotech Psychedelics Markets
From Benzinga
BREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat Depression
Tickers CYBN DEA MDD
Tags MDD DEA Cannabis
From Benzinga
Cybin's Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder
Tickers CYBN
Tags Biotech Markets Psychedelics
From Benzinga
Cybin Closes Fiscal Year 2022, Reports Financial Results And Major Achievements
Tickers CYBN
Tags Penny Stocks Market News Benzinga
From Benzinga
Elon Musk Says Psychedelics Should Be Seriously Considered For Therapeutic Uses, Leading Chorus Of Celeb Support
Tickers CYBN TWTR
Tags Markets Psychedelics TWTR
From Benzinga
Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin
Tickers CYBE CYBN ENTBF
Tags Global ENTBF Cannabis
From Benzinga
Major Depressive Disorder Could Soon Have Treatment Option Via Cybin's Psilocybin Analog
Tickers CYBN
Tags FDA Biotech Psychedelics
From Benzinga
Cybin's Major Depressive Disorder Treatment Trials Continue With Clinilabs Drug Development Corp
Tickers CYBN
Tags Doug Drysdale Cybin Market News
From Benzinga
EXCLUSIVE: How Cybin Is Developing The Next Generation Of Psychedelics
Tickers CYBN DMT PCC
Tags News PCC Exclusives
From Benzinga
A Builder From The Ground Up, Doug Drysdale, CEO of Cybin: Meet Our Speakers
Tickers AGN CYBN PTX
Tags Cannabis Penny Stocks Market News
From Benzinga
Cybin, MindMed, And Field Trip Health Headline PSYC's First CEO Round Table Event
Tickers CYBN FTRP MMDCF PSYC
Tags Ronan Levy Kevin O’Leary David Flores
From Benzinga
Cybin Obtains U.S. Patent For Is Proprietary Compound Deuterated DMT Aimed At Treating Anxiety Disorders
Tickers CYBN
Tags News Cannabis Benzinga
From Benzinga
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
Tickers CYBN FTRP WSNAF
Tags Regulations Cannabis Penny Stocks
From Benzinga
Why Cybin Shares Are Rising
Tickers CYBN
Tags Trading Ideas why it's moving Doug Drysdale
From Benzinga
Cybin Reports Q2 Financial Results And Latest News, Including FDA & DEA Research Approvals
Tickers CYBN
Tags Doug Drysdale Cybin Benzinga
From Benzinga
Cybin Announces Positive Data Showing Effectiveness of Psilocybin To Treat Depression
Tickers CYBN
Tags News Cannabis Penny Stocks
From Benzinga
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
Tickers CMPS CYBN FLHLF NMLSF
Tags CMPS TRYPF FLHLF
From Benzinga
Cybin Becomes First Psychedelics Company On The NYSE: CEO Explains Everything You Need To Know
Tickers CLXPF CMPS GBNH
Tags Markets psychedelics CLXPF
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today